SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): March 8, 2004
TANOX, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-30231 | 76-0196733 | ||
(State or other jurisdiction of incorporation) | (Commission File No.) | (I.R.S. Employer Identification No.) |
| 10301 Stella Link, Suite 110, Houston, Texas | 77025-5497 | |
| (Address of principal executive offices) | (Zip code) |
Registrant’s telephone number, including area code: 713-578-4000
Item 9. Regulation FD Disclosure
TNX-355 is an anti-CD4 antibody designed for the treatment of HIV-1. An end of Phase 1 meeting was held with the Federal Drug Administration (FDA) in late 2003, and the protocol for the Phase 2 trial has been submitted to the FDA. We have selected sites to conduct the Phase 2 trial and have received Investigational Review Board approval for the initial sites. We are in the process of manufacturing the clinical supplies of TNX-355 for the study and currently expect enrollment of the first patient to occur in the first half of 2004.
Tanox’s Chief Medical Officer, William Shanahan, Jr., J.D., M.D., has resigned to accept a position with another company. Dr. Shanahan served as Tanox’s Chief Medical Officer since August 2000. The company will retain an executive search firm to seek a replacement.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 8, 2004 | TANOX, INC. | |||
By: | Jeffrey Organ | |||
Jeffrey Organ | ||||
Chief Operating Officer | ||||
3
